Hikma Pharmaceuticals PLC (LON:HIK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Hikma Pharmaceuticals PLC (LON:HIK) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is GBX 1,939.17 ($24.27).

Several research firms have issued reports on HIK. Barclays boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 ($21.27) to GBX 1,800 ($22.53) and gave the stock an “equal weight” rating in a research note on Wednesday, July 12th. Jefferies Financial Group boosted their price objective on shares of Hikma Pharmaceuticals from GBX 2,080 ($26.03) to GBX 2,125 ($26.59) and gave the stock a “buy” rating in a research note on Monday, May 22nd.

Hikma Pharmaceuticals Price Performance

HIK stock opened at GBX 2,063 ($25.82) on Friday. The stock has a 50-day moving average price of GBX 2,067.80 and a two-hundred day moving average price of GBX 1,894.69. Hikma Pharmaceuticals has a 12-month low of GBX 1,174.50 ($14.70) and a 12-month high of GBX 2,222 ($27.81). The company has a current ratio of 1.79, a quick ratio of 1.27 and a debt-to-equity ratio of 59.58. The company has a market cap of £4.56 billion, a PE ratio of 3,892.45, a price-to-earnings-growth ratio of 1.91 and a beta of 0.43.

Hikma Pharmaceuticals Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 10th were paid a $0.25 dividend. The ex-dividend date was Thursday, August 10th. This represents a dividend yield of 0.95%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 9,245.28%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.